Female is more likely to have complete virological response in Entecavir treatment among chronic hepatitis B patients with positive HBeAg
10.3760/cma.j.issn.1674-2397.2015.01.003
- VernacularTitle:性别是恩替卡韦治疗HBeAg阳性慢性乙型肝炎患者完全病毒学应答的影响因素
- Author:
Youde LIU
;
Wei LIU
;
Jinping LIU
;
Chunjuan WANG
;
Zhengzhong HUA
;
Yucui LIU
;
Yanmei GUO
- Publication Type:Journal Article
- Keywords:
Hepatitis B,chronic;
Entecavir;
Cox's proportional hazards regression model;
Complete virologic response
- From:
Chinese Journal of Clinical Infectious Diseases
2015;8(1):9-13
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the associated factors of complete virological response (CVR) in Entecavir treatment among chronic hepatitis B (CHB) patients with positive HBeAg.Methods Data of 166 CHB patients with positive HBeAg receiving Entecavir treatment in Yantai Infectious Diseases Hospital during December 2009 and May 2014 were collected.Clinical data including age,gender,genotype,baseline alanine aminotransferase (ALT),HBV DNA load,HBsAg and HBeAg levels as well as CVR cumulative rates at different time points during Entecavir treatment were retrospectively analyzed.The cumulative rate of CVR was estimated using Kaplan-Meier method,and the difference in cumulative CVR rates was studied with Log-rank test.Cox's proportional hazards regression model was used to analyze the factors associated with CVR during Entecavir treatment.Results The cumulative rates of CVR during Entecavir treatment in HBeAg positive CHB patients were 54.5％ (87/157),74.3％ (106/129),80.2％ (109/119) and 86.8％ (110/112) at 48,96,144 and 192 weeks,respectively.Log-rank test showed that female patients and patients with genotype B,high baseline ALT level or low baseline HBV DNA load had higher CVR rates (x2 =15.601,11.542,17.021 and 10.094,all P ＜ 0.01).Cox's proportional hazards regression model showed that female was the only associated factor for CVR in Entecavir treatment among HBeAg positive CHB patients [hazard ratio (HR) =3.015,95％ confidence interval (CI):1.875-4.968,P ＜ 0.01].Conclusion CVR rate is increasing with the course of Entecavir treatment in HBeAg positive CHB patients,and CVR is more likely to occur in female patients.
